Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Price:
5.2194 USD
0.96%
Market Closed
Updated:
May 3, 2024
Aurinia Pharmaceuticals Inc
Net Income (Common)
|
Aurinia Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
ZYME
TH
RPTX
FUSN
EDT
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Income (Common)
-$78m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-40%
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Net Income (Common)
-$118.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Net Income (Common)
-$18m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-7%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Net Income (Common)
-$93.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Net Income (Common)
-$94.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Net Income (Common)
-CA$15.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-3%
|
See Also
What is Aurinia Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-78m
USD
-78m
USD
Based on the financial report for Dec 31, 2023, Aurinia Pharmaceuticals Inc's Net Income (Common) amounts to -78m USD.
What is Aurinia Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-40%
-40%
Over the last year, the Net Income (Common) growth was 28%. The average annual Net Income (Common) growth rates for Aurinia Pharmaceuticals Inc have been 9% over the past three years , -4% over the past five years , and -40% over the past ten years .
You don't have any saved screeners yet
